Peptides

CJC-1295/Ipamorelin

A peptide pair positioned around sleep, exercise recovery, body composition, and growth-hormone signaling.

Common goals: Potential support for deeper sleep, exercise recovery, body-composition goals, and a more consistent sense of vitality.
Best program fit: May fit a clinician-monitored performance or healthy-aging offering with metabolic and IGF-1 follow-up.
Format: Clinician-confirmed formulation

Partner education guide

Where this may fit in an offering.

Potential support for deeper sleep, exercise recovery, body-composition goals, and a more consistent sense of vitality. Aims to stimulate the individual’s own pulsatile growth-hormone pathway rather than provide growth hormone directly. A combined protocol offers a simple story around overnight recovery and endogenous hormone signaling.

Educational business-planning summary. Potential benefits vary, are not guaranteed, and require individual-specific clinical review.

01 / Common goals

What people may want to understand.

Primary goals

Potential benefits and goals

Potential support for deeper sleep, exercise recovery, body-composition goals, and a more consistent sense of vitality.
Aims to stimulate the individual’s own pulsatile growth-hormone pathway rather than provide growth hormone directly.
May appeal to adults seeking a clinician-monitored recovery or healthy-aging program with measurable hormone and metabolic follow-up.

Program value

How it may support a program

A combined protocol offers a simple story around overnight recovery and endogenous hormone signaling.
Can be paired with sleep, nutrition, resistance-training, body-composition, glucose, and IGF-1 tracking.

The peptides can raise growth-hormone signals in early human research, but individual-centered wellness outcomes for the blend remain uncertain. Benefits vary and are not guaranteed.

02 / Program fit

Program and operational considerations.

01Administration: Catalog format: Clinician-confirmed formulation. The prescribing clinician and dispensing pharmacy confirm the exact preparation, concentration, handling, and administration technique.
02Typical frequency: Frequency is individualized around the exact formulation, individual goals, tolerability, and monitoring plan.
03Expected duration: Use a defined clinician-directed trial period with baseline measures, scheduled reassessment, and a clear continuation or stopping decision.
04Practical advantages: A combined protocol offers a simple story around overnight recovery and endogenous hormone signaling.

03 / Suitability considerations

Who may be considered.

Who may be considered

A carefully screened adult whose goals align with the potential benefits above and who understands that individual response varies.
An individual willing to complete clinician-directed baseline review, monitoring, and an outcome-based follow-up plan.

Qualification notes

A combined protocol offers a simple story around overnight recovery and endogenous hormone signaling.
Strongest fit occurs when the exact formulation, route, source, contraindications, and measurable goals can be clearly documented.

04 / Safety & suitability

What must be screened before treatment.

Common or temporary

Human blend frequencies are unknown. Potential effects include injection reactions, headache, flushing, dizziness, hunger, water retention, joint discomfort, tingling, and sleep or dream changes.

Serious or important

Growth-hormone and IGF-1 elevation may worsen glucose control, edema, carpal-tunnel symptoms, and untreated sleep apnea; long-term cardiovascular and cancer safety are not established.
Unapproved injection adds contamination, concentration, and sterility risk.

Avoid or use only with specialist input

Active malignancy, pregnancy or breastfeeding, uncontrolled diabetes, severe untreated sleep apnea, proliferative eye disease, acute critical illness, or unverified product identity.
Use in children or adolescents for height, performance, or wellness outside specialist pediatric endocrine care.

Screening checklist

Clarify the CJC molecule and formulation; assess sleep, apnea risk, blood pressure, glucose status, edema, neurologic symptoms, pituitary history, cancer history, medicines, pregnancy status, and baseline IGF-1 when medically appropriate.
Set a clinically meaningful outcome and stopping rule rather than treating a hormone rise as proof of benefit.

When to refer

Suspected pituitary disease, abnormal IGF-1, progressive headache or visual symptoms, marked edema, worsening glucose, or sleep-apnea symptoms requires endocrinology or appropriate medical assessment.

Safety information is not exhaustive. Prescribing, screening, dosing, monitoring, and emergency guidance must come from an appropriately licensed clinician and the exact product information.

What the research says · reviewed August 2026

Research and source context.

Human studies show a hormone signal, not meaningful health outcomes from the blend.

01 / Human research

The clearest clinical signal

Small human studies show each peptide can raise growth hormone. No good trial shows the pair improves sleep, muscle, fat, or recovery.

02 / Real-world reports

What people describe

About 10 detailed accounts were sampled. Deeper sleep and recovery were the most common claimed benefits after 1-4 weeks. Several saw no body change. Water retention, tingling, hunger, headache, vivid dreams, injection reactions, and higher glucose were recurring complaints.

Public personal accounts are unverified and cannot show how common an outcome is.

03 / Cautions

What deserves attention

Injection reactions, headache, flushing, swelling, joint or nerve pain, and higher blood sugar may occur. Growth signals can raise IGF-1. Long-term cancer and heart safety for wellness use are not known.

Does the research match this exact product?

Separate short studies do not prove that the combined catalog product works.

Complete evidence briefClinical summary, safety notes, reported timing, regulatory context, and linked sources in one document.

Download the evidence briefPDF · larger type

Evidence and regulatory status can change. Confirm the current label, formulation, route, dose, pharmacy source, jurisdiction, and intended use before offering treatment.

Education before offering.

Treatment information is for education only. It is not medical advice. A licensed clinician will review your health and decide whether a treatment is appropriate for you. Eligibility and availability may vary.

Back to all treatments